Monitoring & Safety on Gender-Affirming T
Erythrocytosis, Lipids, Cardiovascular Risk, and Bone Health in Transmasculine Cohorts
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Off-label; monitoring per WPATH SOC-8 and Endocrine Society (Hembree 2017)
Reference only. Not medical advice.
This is something to take to a clinician. The Atlas can tell you what is known about monitoring & safety on gender-affirming t in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The best-documented metabolic effect of gender-affirming testosterone is erythrocytosis: in a large Dutch cohort (Madsen/Defreyne et al., JCEM 2021, ~1,073 trans men), roughly 11% developed a hematocrit above 0.50 L/L on at least two occasions, with intramuscular long-acting esters, smoking, older age at initiation, and higher BMI raising risk. Testosterone reliably lowers HDL and raises LDL/triglycerides. On hard cardiovascular endpoints, cohort data (e.g., Getahun/Kaiser Permanente; Belgian cohorts) have been largely reassuring for myocardial infarction and stroke versus controls, though follow-up is relatively short and confounded. Bone density is generally preserved or increased on testosterone (Van Caenegem; ENIGI), and the Wiepjes nationwide fracture study did not show a clear excess fracture risk in trans men. Long-term, multi-decade outcome data remain genuinely limited.
The data are largely reassuring on hard cardiovascular endpoints, but long-term, high-quality evidence is still limited. Monitor accordingly.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Testosterone stimulates erythropoiesis (raising hematocrit) and aromatizes to estradiol, while androgenic effects on hepatic lipid handling lower HDL and raise LDL/triglycerides. Maintained estradiol exposure from aromatization, plus androgenic and mechanical loading effects, helps preserve bone in trans men who retain gonads or maintain adequate sex-steroid levels.
Reassuring is not the same as proven safe long-term
Short- and medium-term cohorts have not shown a clear excess of heart attack or stroke in trans men, and bone density holds up. But these studies are observational, relatively short, often single-center or registry-based, and underpowered for rare hard endpoints over decades. The lipid shift (lower HDL, higher LDL) and erythrocytosis are real and measurable; whether they translate into excess long-term cardiovascular events with lifelong exposure is not yet established. Honest framing: largely reassuring so far, but the multi-decade evidence base is thin.
Safety in detail
This intervention requires baseline and ongoing laboratory monitoring under a qualified clinician. Erythrocytosis in particular is common, dose- and formulation-related, and managed by dose adjustment, formulation change, or therapeutic phlebotomy.
- Erythrocytosis/polycythemia, the most consistent and monitorable risk; check hematocrit at baseline, during titration, and periodically
- Dyslipidemia, falling HDL, rising LDL/triglycerides; monitor lipids
- Possible blood-pressure and weight changes
- Acne and androgenetic alopecia (cosmetic but common)
- Pelvic/vaginal atrophy (see pelvic-health entry)
- Long-term cardiovascular and oncologic outcomes incompletely characterized
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Hematocrit/hemoglobin at baseline, during titration, then periodically
- Lipid panel
- Total testosterone (trough), titrated to a typical male range
- Blood pressure and weight
- Clinical review of symptoms and virilization
What people get wrong
Often saidTestosterone wrecks the heart
ActuallyCohort data to date do not show a clear excess of myocardial infarction or stroke in trans men versus controls, though lipids shift adversely and follow-up is limited. The honest statement is 'reassuring but not definitive,' not 'dangerous' or 'proven safe.'
Often saidTestosterone weakens bones in trans men
ActuallyThe opposite trend is seen: bone density is generally preserved or increased on testosterone, and a nationwide cohort did not show clear excess fractures. Bone risk rises mainly if gonads are removed and sex-steroid levels are then allowed to fall.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
What we do not know
- What is the multi-decade cardiovascular event rate with lifelong testosterone in trans men?
- Does the adverse lipid shift translate into excess clinical events over time?
- How does gonadectomy timing interact with long-term bone and cardiovascular risk?
At a glance
- Erythrocytosis (Hct >0.50 x2)
- ~11% in a ~1,073-person Dutch cohort
- Higher-risk factors
- IM long-acting esters, smoking, older start age, BMI >30
- Lipids
- HDL falls; LDL and triglycerides tend to rise
- MI/stroke
- Largely reassuring in cohorts; short follow-up
- Bone density
- Generally preserved or increased on testosterone
- Fractures
- No clear excess in trans men (Wiepjes nationwide cohort)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Monitoring & Safety on Gender-Affirming T. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- What can go wrong. We have not written the risk line for this one. Read the safety section below rather than treating its absence as reassurance.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Erythrocytosis in a large cohort of trans men using testosterone (Madsen, Defreyne, et al., JCEM)2021
~1,073 trans men; ~11% had hematocrit >0.50 L/L twice; IM esters, smoking, older age, higher BMI raised risk
Cross-sex hormones and acute cardiovascular events (Getahun et al., Annals of Internal Medicine)2018
Kaiser Permanente cohort (~2,118 transmasculine members); no clear excess MI/stroke signal in trans men over mean ~3.6 years
Bone mass/geometry in trans men on testosterone (Van Caenegem; ENIGI program)2012-2015
Bone mineral density generally maintained or increased during testosterone treatment
Fracture risk in trans men and trans women (Wiepjes et al., J Bone Miner Res)2020
Nationwide cohort; no clear excess fracture risk attributable to testosterone in trans men